ICU Medical Incorporated (ICUI) : Gw&k Investment Management scooped up 2,798 additional shares in ICU Medical Incorporated during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 11, 2016. The investment management firm now holds a total of 542,184 shares of ICU Medical Incorporated which is valued at $62,340,316.ICU Medical Incorporated makes up approximately 1.27% of Gw&k Investment Management’s portfolio.
Other Hedge Funds, Including , Bnp Paribas Arbitrage Sa boosted its stake in ICUI in the latest quarter, The investment management firm added 2,355 additional shares and now holds a total of 4,528 shares of ICU Medical Incorporated which is valued at $520,720.
ICU Medical Incorporated closed down -0.24 points or -0.21% at $114.98 with 64,893 shares getting traded on Wednesday. Post opening the session at $115.94, the shares hit an intraday low of $114.24 and an intraday high of $116.77 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, ICU Medical Incorporated reported $1.14 EPS for the quarter, beating the analyst consensus estimate by $ 0.16 according to the earnings call on May 10, 2016. Analyst had a consensus of $0.98. The company had revenue of $89.80 million for the quarter, compared to analysts expectations of $88.04 million. The company’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.60 EPS.
ICU Medical Inc. is engaged in the development manufacturing and sales of medical devices used in infusion therapy oncology and critical care applications. The Companys product line includes needlefree connection devices custom infusion sets closed system transfer devices (CSTD) for the handling of hazardous drugs advanced sensor catheters needlefree closed blood sampling systems disposable pressure transducer systems and innovative hemodynamic monitoring systems. The Companys products are used in acute care hospitals and ambulatory clinics in more than 60 countries worldwide. Its products are categorized into three market segments: Infusion Therapy Critical Care and Oncology. Its primary products include MicroClave and MicroClave Clear Anti-Microbial MicroClave Tego needlefree hemodialysis connector Transpac disposable pressure transducers Pulmonary artery thermodilution catheters ChemoLock CSTD and components and Diana hazardous drug compounding system among others.